Latest / CLEs You Actually Want to Hear / The Nuts and Bolts of Federal and State Vaping Laws
Transcript
- 0:03Hello, everyone, and welcome to today's program,
- 0:07The Nuts and Bolts of Federal and State Vaping
- 0:09Laws. I'm Ola Policastro, Director of Education
- 0:13and Professional Development at Beverly Hills
- 0:15Bar Association. And today I'm delighted to introduce
- 0:18our speaker, Azim Chowdhury. Azim is a partner
- 0:22at Keller and Heckman LLP in Washington, D .C.
- 0:25and is a nationally recognized authority on tobacco,
- 0:28nicotine, product regulation, advising domestic
- 0:31and international clients on complex compliance
- 0:34issues before the US Food and Drug Administration
- 0:37and global regulators. His practice focuses on
- 0:40the evolving legal landscape governing tobacco,
- 0:43e -vapor, and next generation nicotine products.
- 0:46He counsels manufacturers, distributors, and
- 0:49trade associations on regulatory strategy, public
- 0:52policy, and product approvals. In addition to
- 0:55his advisory work, he's a prominent thought leader,
- 0:58author, and speaker on tobacco regulation, contributing
- 1:01to key industry publications and initiatives
- 1:03that influence the direction of regulatory policy
- 1:07and compliance practices in this highly scrutinized
- 1:10sector. We're so excited to have him here with
- 1:12us today, so I'm going to turn it over to him.
- 1:15Great. Thank you for having us, for having me,
- 1:18and for those of you who are attending live,
- 1:21thank you for joining and missing the first few
- 1:23hours of March Madness. But we only have an hour
- 1:27today, so I am going to go ahead and jump right
- 1:29into this. See if I can share my screen here.
- 1:35Where did it go? Okay, I think it's working if
- 1:51it's not please Please let me know but um, we
- 1:55don't see your screen right now. Okay. Hold on
- 1:59a second here Screen two about that It's perfect
- 2:08Okay, fantastic All right. Well, um, yeah, we're
- 2:13here today to talk about the exciting world of
- 2:16vaping e -cigarettes and a little bit about other
- 2:19nicotine products as well, which is now under
- 2:23heavy FDA regulatory scrutiny. But first, a little
- 2:28bit of background on Keller & Heckman. We are
- 2:32a law firm based in Washington, DC, but with
- 2:35a global presence with offices in San Francisco,
- 2:38Boulder, Brussels, and Shanghai. Established
- 2:41back in 1962, we are about 80 attorneys globally
- 2:46with about 20 scientific staff, which makes us
- 2:50a bit unique because we do focus heavily on regulatory
- 2:53and technical submissions. If you have any questions
- 2:57about any type of FDA environmental or regulatory
- 3:02issue, please feel free to reach out. Very quickly,
- 3:07just quick plug. We host our annual e -vapor
- 3:12nicotine and tobacco law symposium every year
- 3:16in Las Vegas. This upcoming event is going to
- 3:21be the 10th annual one, so a big deal for us.
- 3:25Please feel free to join us. It's a good event.
- 3:27It covers the things we're talking about today
- 3:30and much more over two days. And it's well attended
- 3:35by folks in the industry and their attorneys.
- 3:39So if this is of interest to you, please feel
- 3:41free to reach out and register. All right, so
- 3:45the focus of today's discussion is going to be
- 3:48vaping. What that means is using e -cigarettes
- 3:51or electronic cigarettes. So before I get into
- 3:54the legal issues, I thought for those of you
- 3:56who may not be as familiar with these products,
- 3:59a brief background might be helpful. So e -cigarettes
- 4:03are battery -powered devices that do not contain
- 4:07any tobacco material, tobacco leaf, but rather
- 4:11contain what's called an e -liquid that is a
- 4:14solution of components like different bases such
- 4:20as propane glycol, glycerin, flavor compounds,
- 4:23and of course nicotine. The way e -cigarette
- 4:27works is the e -liquid here, which is contained
- 4:31in a storage unit, is heated by what's called
- 4:36an atomizer. that turns the liquid into a vapor
- 4:40that can be inhaled by the consumer. There are
- 4:45different types of e -cigarettes, primarily in
- 4:49two different categories. What are called closed
- 4:51systems, which initially were called cigalikes
- 4:54because they were designed to look like a traditional
- 4:57cigarette. But now you see both open systems
- 5:01and closed systems. The main difference between
- 5:04an open system and a closed system, is that a
- 5:07closed system is a completely sealed unit with
- 5:10the e -liquid pre -filled by the manufacturer,
- 5:15whereas an open system comes in two different
- 5:17pieces. You have the hardware component, which
- 5:20is a device with a tank that can be refilled
- 5:24with e -liquid, the flavored e -liquids that
- 5:28consumers can purchase on their own and they
- 5:30can use whatever eLiquid of their choice with
- 5:34their reusable open system device. Within the
- 5:39closed system category, you have two different
- 5:43main subcategories. You have pod systems, which
- 5:48if you're familiar with a popular device called
- 5:50the Joule, that's a pod system example where
- 5:53there is a component that is pre -filled, again,
- 5:57because it's closed system, but once the user
- 6:00consumes the e -liquid in the pod or the cartridge,
- 6:05they dispose of that cartridge and then can use
- 6:07another cartridge which could be a different
- 6:08flavor, for example. Disposable e -cigarette
- 6:11or a vapor product is just like a pod system
- 6:15except there's no pod. The whole thing is pre
- 6:19-filled and is disposed of once it has been consumed.
- 6:28All right, so now we're going to jump into the
- 6:29legal framework. So this all started, believe
- 6:33it or not, way back in 2009, which I say way
- 6:37back, but really wasn't that long ago when you
- 6:39think about things that FDA regulates. But it
- 6:42was back in 2009 that FDA was given the authority
- 6:45to regulate tobacco products for the first time
- 6:48when Congress passed the Tobacco Control Act.
- 6:52What that law did was give FDA authority over
- 6:56all things that contain substances derived from
- 7:00tobacco. made or derived from tobacco. Prior
- 7:03to this law, FDA actually did not have any authority
- 7:07over tobacco products. That's not to say there
- 7:10was no laws around the use of these products,
- 7:14there were, but mainly in the form of advertising
- 7:18restrictions, warning labels, et cetera, that
- 7:20were by and large regulated by the Federal Trade
- 7:24Commission. And at the state level, in terms
- 7:28of where products could be used, where they could
- 7:30be smoked, for example. But there was no actual
- 7:33federal oversight over the manufacturing of these
- 7:35products, the ingredients, how they're made,
- 7:38what goes into them, how they're marketed at
- 7:41the federal level. That changed in 2009. But
- 7:44the key thing is, even though FDA was given authority
- 7:48over, again, broadly, anything made or derived
- 7:51from tobacco, The statute, the Tobacco Control
- 7:54Act, only gave FDA the authority initially over
- 7:57certain categories of tobacco products. So those
- 8:01are the traditional products that I refer to,
- 8:03which are cigarettes, smokeless tobacco, chewing
- 8:06tobacco, and roll -your -own tobacco. Those are
- 8:10the only initial kind of categories of products
- 8:13that were subject to FDA's immediate authority.
- 8:17What the Congress did say, was that to the extent
- 8:22there are other products that meet the definition
- 8:24of a tobacco product, it would be up to FDA to
- 8:28promulgate a regulation to capture those products.
- 8:32So FDA would have to go through a rule -making
- 8:33process to decide what other categories of products,
- 8:37whether those are e -cigarettes or ends, as we
- 8:39call them, cigars, heated tobacco products. Today
- 8:44we're seeing a lot of oral nicotine pouches,
- 8:46which I'll talk about. All of those would be
- 8:48considered products that would be subject to
- 8:50FDA's authority following their deeming of them
- 8:54to be tobacco products. And so there was this
- 8:57kind of regulatory gap between the initially
- 9:02regulated products in 2009 and until FDA passed
- 9:05a rule extending that authority to other products,
- 9:09which they finally did in 2016 with what's called
- 9:11the deeming rule. And then in 2022, There was
- 9:17another change to the law. This one was a change
- 9:19to the statute itself where Congress redefined
- 9:24tobacco product in the TCA to include not just
- 9:29products made or derived from tobacco, but products
- 9:32that contain nicotine from any source. The reason
- 9:35for that, as we'll see, is because there was
- 9:39this loophole where synthetic nicotine, or nicotine
- 9:44that is not derived from tobacco was not under
- 9:47FDA's authority. And once companies started realizing
- 9:52this, we saw a shift to synthetic nicotine in
- 9:572020, 2021 by companies seeking to avoid the
- 10:01authorities, the regulation, but that was nipped
- 10:05in the bud in 2022 with the amendment to the
- 10:08law. A quick note here, you'll see I mentioned
- 10:11pre -existing or grandfathered products. As we'll
- 10:14see, the main requirement for tobacco products
- 10:18under the TCA is the requirement for pre -market
- 10:21authorization. A pre -existing product is a product
- 10:26that was already on the market prior to or as
- 10:29of February 15, 2007, which is known as a grandfather
- 10:34date. So we'll talk a little about that in a
- 10:36moment. So in terms of the requirements of the
- 10:40TCA, The main ones are listed here include registration
- 10:46of tobacco manufacturing establishments. So any
- 10:49location where tobacco products are being made
- 10:51or packaged would have to register that facility
- 10:55with FDA if they are located in the domestic
- 10:58US. That requirement does not apply to foreign
- 11:03manufacturing establishments. That's been a big
- 11:07issue for many years. It's impacted the enforcement
- 11:10of this category, and we're seeing FDA just recently
- 11:14announce efforts to extend the registration requirements
- 11:18to foreign establishments. Companies are required
- 11:22to report their ingredients to FDA in terms of
- 11:26what is being used in those products. including
- 11:29tobacco and when it comes to e -cigarettes, the
- 11:31e -liquid components. They're required to update
- 11:34FDA with respect to any health documents. So,
- 11:37those are studies that are done on the safety
- 11:40of the products, etc. Those have to be separately
- 11:43submitted to FDA. separate from the pre -market
- 11:47authorization requirement for certain categories
- 11:49of products. Then you have a variety of labeling
- 11:52and nicotine addiction warning requirements that
- 11:57need to be both on the product and at the point
- 11:59of sale. And we separately have a requirement
- 12:03as of 2021, the federal age to purchase tobacco
- 12:08was raised to 21 years old. But all those are
- 12:12relatively easy in terms of regulatory compliance.
- 12:17What's difficult about the TCA and the FDA regulation
- 12:21is the requirement for pre -market authorization.
- 12:26So I'm going to talk briefly about the different
- 12:28pre -market pathways. There's three of them.
- 12:32There's substantial equivalence, which applies
- 12:37primarily to those original statutory products,
- 12:41cigarettes, smokeless tobacco, and roll your
- 12:43own tobacco. The reason is because substantial
- 12:47equivalence requires that there be a grandfathered
- 12:51predicate product that the new product can compare
- 12:55itself to, right? So again, all new tobacco products
- 12:59that are not grandfathered need to go through
- 13:03pre -market authorization. means they have to
- 13:06be approved or authorized for sale by FDA, affirmatively.
- 13:10Only grandfather products that were on the market
- 13:13in commercial distribution prior to the grandfather
- 13:15date are exempt. So cigarettes, which are the
- 13:21most prevalent still and most harmful tobacco
- 13:24product, because those products have been around
- 13:27for a long time, and the companies that produce
- 13:30those products have evidence that they were selling
- 13:33those. for many years, they are largely grandfathered
- 13:37and exempt from pre -market review. To the extent
- 13:40a cigarette company, for example, wants to make
- 13:43a change to their product, either to the type
- 13:45of tobacco or the filter or the paper, they would
- 13:48have to go through pre -market review, which
- 13:52would trigger, for example, which would trigger
- 13:54here, substantial equivalence. And the standard
- 13:57for that is to demonstrate that the product,
- 14:00that the change that they're making to that cigarette,
- 14:02to the paper, to the filter, what have you, does
- 14:05not raise new or different questions of public
- 14:07health. What it basically means is the FDA wants
- 14:10to make sure if you're making a change to a product
- 14:12that's grandfathered that that change is not
- 14:15going to make it more harmful or more addictive.
- 14:20Then you have the what's called substantial equivalence
- 14:23exemption request, which again, it applies to
- 14:26the same category of pre -existing or grandfather
- 14:29products looking to make changes. Basically,
- 14:32it's for very minor changes to additives in the
- 14:36pre -existing or grandfather product that are
- 14:38so minor that they don't qualify for the full
- 14:41-blown substantial equivalence process. So it's
- 14:44fairly limited use. But again, that also requires
- 14:48a predicate. pre -existing products. The bulk
- 14:51of what we're going to talk about today is the
- 14:53PMTA, pre -market tobacco application, because
- 14:56that is what applies to vapor products or e -cigarettes.
- 15:01The reason the PMTA is the only pathway that
- 15:04applies to vaping products is because there are
- 15:08no grandfathered versions of vaping products.
- 15:11The first e -cigarettes came to market in the
- 15:13US late in 2007. is what we have discovered in
- 15:19early 2008 from China. And so the earliest known
- 15:24e -cigarette that was sold in the US just barely
- 15:29missed that sort of grandfather deadline in February
- 15:332007. And so what that means is the entire category
- 15:38of e -cigarettes is considered a new product.
- 15:41And so every single product in order to be sold
- 15:44legally, needs to go through the PMTA process.
- 15:50Now, what's interesting about this process is
- 15:52that the standard, the legal standard for authorization
- 15:55is demonstrating that the product is appropriate
- 15:59for the protection of the public health. Well,
- 16:01what does that mean? Well, it's a very high standard,
- 16:05right? If you're familiar with FDA, you might
- 16:07have heard of the safe and effective standard
- 16:09that applies to drugs. This is similar because
- 16:14it does require assessing the risks of the product,
- 16:17the safety of the product to the individual consumer.
- 16:19But in my view, it's an even higher standard
- 16:22because it requires assessing the population
- 16:25level effect. FDA says that for a product to
- 16:30be a PPH, the company must demonstrate the overall
- 16:35benefit to the population as a whole of that
- 16:39product, including both users and non -users.
- 16:41taking into account the potential for increased
- 16:44or decreased cessation. What does that mean?
- 16:46Cessation means, does the introduction of the
- 16:49new product help people essentially quit smoking,
- 16:52right? As well as the potential for increased
- 16:56or decreased initiation. What does that mean?
- 17:00It means, well, does the availability of this
- 17:02new product, could it impact people initiating
- 17:06into tobacco or nicotine use, in particular youth?
- 17:10We don't want kids to start using nicotine or
- 17:13tobacco. And so how does the availability of
- 17:17this product impact the overall youth rates of
- 17:21tobacco use? And so these are all the types of
- 17:24things that must be considered in a variety of
- 17:27different types. of studies, including clinical
- 17:30trials, behavioral studies, population modeling
- 17:33studies. It's a wide -range, multidisciplinary
- 17:37effort that can cost millions of dollars to prepare.
- 17:43In terms of resources, there's no one -stop shop
- 17:46guide to what's required. It's been a bit of
- 17:51a jigsaw puzzle for many years, trying to figure
- 17:54out What is required? What studies does the company
- 17:57have to do for different types of vaping products
- 18:00with different types of flavors? An FDA has over
- 18:03the years, since the deeming rule in 2016, we
- 18:07have seen a number of guidance documents that
- 18:09have been published on the requirements for PMTAs
- 18:14and e -cigarettes. We have seen a final rule
- 18:17that went through a separate rulemaking process
- 18:19that became final at the end of 2021. We have
- 18:24a variety of what are called regulatory science
- 18:26policy memoranda that FDA publishes from time
- 18:29to time providing details on their internal review
- 18:32in terms of different disciplines like chemistry,
- 18:35toxicology, et cetera. Then FDA from time to
- 18:38time will have public meetings where they have,
- 18:41you know, they open the door to the industry,
- 18:44to stakeholders, to ask questions, to presentations.
- 18:49And recently they had a round table discussion
- 18:51on for small companies in this space seeking
- 18:56into PMTAs. These are types of resources out
- 18:59there that you or your clients might be looking
- 19:03to find if you're looking to prepare a PMTA.
- 19:07In terms of the PMTA process, there are several
- 19:11steps. First is, if you're able to, You recommend
- 19:17meeting with FDA and proposing to them your strategy
- 19:20for your studies, your testing protocols, et
- 19:23cetera, to get an idea of whether or not you're
- 19:26going down the right path for a PMTA. Once a
- 19:29PMTA is submitted after that potential pre -meeting,
- 19:33it goes through three phases, acceptance, filing,
- 19:37and then scientific review. This acceptance phase
- 19:41is more of an administrative phase, meaning companies
- 19:44that the PMTAs are reviewed to ensure they have
- 19:47the right forms, that all the products are covered,
- 19:51that the product that's covered is in fact a
- 19:54tobacco product. Sometimes people submit applications
- 19:57for things that don't actually qualify for the
- 20:01PMTA process, that you've included all the right
- 20:04basic information in terms of labeling, ingredients,
- 20:06environmental assessments, et cetera. Companies
- 20:09will then receive an acceptance letter and the
- 20:13PMT will move on to the filing stage. Filing
- 20:16is a bit more of a scientific review, like a
- 20:22mini scientific review where they look to see,
- 20:25did the company actually include data? Did they
- 20:28include information on test results for harmful
- 20:31chemicals, stability of the product over time?
- 20:34Did they do a clinical trial? And if it looks
- 20:37like at a preliminary level, they've included
- 20:40that information, then it will go on into scientific
- 20:44review. There are rules that you should look
- 20:48closely at if you're submitting a PMTA to understand
- 20:51specifically what the requirements are and what
- 20:55to avoid to prevent a refuse to accept, for example.
- 21:00So here are some of those of CFR citations that
- 21:05identify again, you know, the right forms, making
- 21:08sure you have the right environmental assessments
- 21:12for the product, to the extent there is a foreign
- 21:15language documentation in the PMCA that must
- 21:19be accompanied by a certified translation. So
- 21:24yeah, those are the types of things that FDA
- 21:25is looking for, and they will. I mean, FDA in
- 21:28this category, they will refuse an application,
- 21:34even if it is comprehensive, even if it costs
- 21:37millions of dollars, if you did not sign the
- 21:40right document, or if you did not include the
- 21:43right form. So it is very critical that you know
- 21:46exactly what to look for and how to avoid those
- 21:48mistakes. Again, when it comes to the filing
- 21:51process, that secondary review, I would look
- 21:55closely at the CFR for the PMTA final rule. because
- 22:00that includes kind of the more specific information
- 22:03that we have now in terms of full information
- 22:06that they're looking for on the health risks,
- 22:09the manufacturing, labeling. What we see now
- 22:13is that they're looking specifically for evidence
- 22:16that the company did the key studies required
- 22:19for scientific review. And if that evidence is
- 22:22not there, that those studies were conducted,
- 22:26FDA will refuse to file the application because
- 22:29it doesn't make sense for them to spend the resources
- 22:31to review an application that doesn't have all
- 22:34the information. Then finally, when it comes
- 22:38into the final phase scientific review, this
- 22:42is where you get into the real meat of the PMTA.
- 22:45For companies that are doing this the right way,
- 22:47This is where all the evidence and all the data
- 22:50is reviewed, including engineering data, toxicology,
- 22:54behavioral, clinical pharmacology, microbiology,
- 22:58again, population health impact assessments,
- 23:02perception and use of the product. Again, many
- 23:06different types of studies. It would take a full
- 23:09day seminar like the one that we host in May
- 23:11to go over all of them to understand what is
- 23:15required for a PMTA. So you might wonder, well,
- 23:22if the PMT process is so difficult and so hard
- 23:24and so time consuming, how is it that there are
- 23:29so many products on the market? Because if you
- 23:31go into a gas station or a vape shop, you'll
- 23:34see many thousands or hundreds of products available
- 23:37in all sorts of flavors. And many of those are
- 23:41not authorized for sale, because we'll talk about
- 23:44how few of those have been authorized. The reason
- 23:48in part is because over the years there have
- 23:50been what are known as deferred enforcement compliance
- 23:53policies. The way this all kind of worked out
- 23:57over time created a lot of confusion in the marketplace
- 24:01and, you know, an enforcement discretion from
- 24:04FDA because, as I mentioned, early on there was
- 24:06this, the law became effective in 2009 and e
- 24:12-cigarettes, although they were on the market,
- 24:14and started coming to market around that time
- 24:16period were not subject to regulation until well
- 24:20later, until seven years later, until 2016 when
- 24:23FDA passed the deeming rule. So there was this
- 24:25period of time when these products were on the
- 24:28market without any real regulatory oversight.
- 24:32By the time FDA passed that deeming rule in 2016,
- 24:36they knew there was already a multi -billion
- 24:38dollar industry many hundreds of companies, small
- 24:42businesses, vape shops, people were selling these
- 24:44products, and rather than say automatically on
- 24:49day one of the deeming rule, effective date,
- 24:52that everyone was illegal, they said, we're going
- 24:55to create a deferred enforcement policy whereby
- 24:57if you're already on the market by the time this
- 25:00rule became effective on August 2016, we're going
- 25:04to allow you to stay on the market for some period
- 25:07of time. While we figure out what we need for
- 25:11a PMTA. Because again, it wasn't until 2021 that
- 25:14we got the PMTA rule from FDA, final rule from
- 25:17FDA on what's required for a PMTA. And so companies
- 25:20were complaining and there was litigation about,
- 25:23well, how can FDA require us to do PMTAs and
- 25:28not tell us what's needed to be in a PMTA or
- 25:30what's needed to meet the statutory standard?
- 25:33because this is all brand new for FDA. And so
- 25:35there was this periods of time that lasted for
- 25:37several years where FDA said companies could
- 25:39stay on the market pending their PMTAs if they
- 25:47submitted one while they review those applications
- 25:50because of how long it was taking them to figure
- 25:52out what they wanted. So there was an initial
- 25:54PMTA deadline in September 2020. for tobacco
- 25:58-derived nicotine, then as I mentioned, in May
- 26:012022, there was another deadline for synthetic
- 26:04nicotine once that came under FDA's authority.
- 26:08Okay, but as of today, right now, if you call
- 26:10an FDA and ask them, is there a deferred enforcement
- 26:14policy, they would say no. Those periods of time
- 26:17have come to an end. They were limited in time.
- 26:20There was some litigation I don't have time to
- 26:22get into on this webinar. that forced the initial
- 26:26deadline and then the end of that compliance
- 26:28policy or the deferred enforcement policy in
- 26:322021. But so the result of all that, to boil
- 26:36it down, is that today there is no formal enforcement
- 26:41discretion. FDA's position is that to sell a
- 26:43vapor product, it must be authorized through
- 26:46the PMTA process. We're not formally extending
- 26:49enforcement discretion. However, as a practical
- 26:52matter, we know that That's not true. That FDA,
- 26:56that there is enforcement discretion because
- 26:57there are products on the market that are on
- 27:00the market without authorization and FDA is not
- 27:03enforcing. It may be because they have pending
- 27:06applications. It may be because of other reasons.
- 27:08They have to prioritize, right? They don't have
- 27:11unlimited resources. And so FDA focuses their
- 27:14priorities on sort of the most, you know, violative
- 27:18products typically. All right, so back to the
- 27:20PMTA. There have been these deadlines over the
- 27:25years, and the result of the PMTA process has
- 27:29been that overwhelmingly, the vast majority,
- 27:32over 99 % of PMTA's four vapor products over
- 27:36the years have either been refused or denied.
- 27:39Again, part of that was because of the lack of
- 27:42guidance from FDA on what was required, how much
- 27:46it costs to submit a PMTA, and really just kind
- 27:50of a mess of an enforcement situation. What we
- 27:54ended up seeing happen in late 2021 was FDA started
- 28:00to focus on flavors. And because their concern
- 28:03was youth, young people were starting to use
- 28:07vaping products. In 2019, you might recall there
- 28:10was a huge public health concern about youth
- 28:13vaping and Juul and all sorts of concerns about
- 28:18these products being on the market and being
- 28:21subject to almost no authority. And so what FDA
- 28:25did as they started reviewing the PMTAs that
- 28:29started coming in, in 2020, was they created
- 28:32what's called a comparative efficacy standard.
- 28:36Okay, what does that mean? FDA's position was
- 28:39that in order to meet the statutory APPH standard
- 28:43appropriate for the protection of public health,
- 28:45PMTAs for vapor products needed to include robust
- 28:50data. in the form of a longitudinal study or
- 28:55a randomized clinical trial, demonstrating that
- 28:59the non -tobacco flavored product was more effective
- 29:03at promoting adults to switch or quit smoking
- 29:08or reduce cigarette consumption above and beyond
- 29:11that of a tobacco flavored product. What does
- 29:15that mean? That was pretty confusing. What it
- 29:17means is that FDA's presumption is that a flavored
- 29:21product is attractive to youth and therefore
- 29:24raises public health concerns because we don't
- 29:27want kids starting to use nicotine products.
- 29:30So if a company wants to sell a non -tobacco
- 29:33flavored product, they have to do a specific
- 29:36type of study to show why that flavored product
- 29:39is more effective at getting smokers, cigarette
- 29:43smokers, to switch or reduce their cigarette
- 29:46consumption. over and above that of a tobacco
- 29:50flavored. So if you're a tobacco flavored vape,
- 29:53then you don't have to do this study because
- 29:56the data shows that kids don't like those vapes.
- 30:00But if you're anything else, a mango flavor,
- 30:02a fruit flavor, a dessert flavor, then you have
- 30:05to demonstrate this additional benefit over and
- 30:07above a tobacco flavor in order to overcome that
- 30:11assumption, that presumption that kids will like
- 30:14and likely use potentially the flavored product.
- 30:18OK, so that was a lot. And that all kind of came
- 30:22about suddenly from FDA in 2021 as they were
- 30:27reviewing these PMTs that had been submitted
- 30:30in September 2020, that first deadline. And FDA,
- 30:35what has come about since then, basically came
- 30:37up with this standard and what they call the
- 30:39fatal flaw. So again, if your product does not
- 30:42contain this particular type of study, it was
- 30:44going to be automatically denied. And so going
- 30:50back to that PMTA review, this is kind of how
- 30:54it played out in reality. Companies had submitted
- 30:56applications. They had met the filing requirement
- 31:00to then have the application proceed to scientific
- 31:05review. But FDA came up with a new kind of step
- 31:09right before the actual scientific review, whereby
- 31:14they looked for this particular type of comparative
- 31:16advocacy study. They said this was a fatal flaw.
- 31:19If your PMT doesn't contain this robust data
- 31:24that demonstrates switching or for your favorite
- 31:29product, if it doesn't contain that study, we're
- 31:33not going to look at anything else in the application.
- 31:35We're not going to look at your marketing plan.
- 31:37We're not going to look at what other data you
- 31:39might have to support your application. we're
- 31:44going to deny the application out the gate because,
- 31:48number one, they've received millions of applications.
- 31:52They received, I think, somewhere between seven
- 31:57to eight million PMTAs before that first deferred
- 32:02enforcement policy deadline in September 2020.
- 32:05They were completely inundated and had no real
- 32:09way of processing those applications efficiently.
- 32:12And so again, they came up with this fatal flaw
- 32:15review that basically required the study. And
- 32:22if it wasn't there, they denied the application.
- 32:25And so we know that because they actually had
- 32:27checklists. So companies who had their applications
- 32:29denied, who eventually got copies of their FDA
- 32:33decision memos, saw that there was this checkboxes.
- 32:38where they look specifically for the presence
- 32:41or evidence of a randomized control trial or
- 32:44a longitudinal study assessing this comparative
- 32:47benefit to a tobacco -flavored product. And if
- 32:51that application did not contain that data, again,
- 32:55it was automatically denied. This caught most
- 32:59of the industry completely by surprise, right?
- 33:04argued, as we'll see in litigation, that FDA
- 33:07did not give sufficient fair notice that this
- 33:10particular type of study was going to be kind
- 33:13of the be -all end -all of the PMTA. And so as
- 33:18soon as companies started getting these denials,
- 33:20they were mass denied. So in the beginning of
- 33:23September 2021, you'll see FDA press releases
- 33:26where they denied hundreds of thousands of applications
- 33:29kind of all on the same day. It was mass denials
- 33:33and put the whole industry in jeopardy. And so
- 33:37companies started challenging FDA. In section
- 33:40912 of the Tobacco Control Act, there is a provision
- 33:43that allows companies to, within 30 days of getting
- 33:46an MDL, a marketing denial order, they can petition
- 33:49for judicial review in their home circuit. And
- 33:53so at least 50, if not more, appeals were filed
- 33:57within the next few months in different circuits
- 34:00around the country. as well as the number of
- 34:04probably hundreds of administrative review requests
- 34:08and petitions to FDA, arguing that FDA had not
- 34:13provided fair notice, that FDA's denials were
- 34:17arbitrary and capricious under the Administrative
- 34:20Procedure Act. So of those many, many cases,
- 34:25there were a number of several key cases I want
- 34:28to highlight. The first was bitty vapor in the
- 34:3211th circuit. That was a case where the company
- 34:37had a disposable vapor product that came in multiple
- 34:41flavors. They argued they had completed a multimillion
- 34:46dollar application that included a variety of
- 34:50different types of studies. But they didn't have
- 34:53that specific comparative efficacy study and
- 34:56received the boilerplate MDO from FDA. They challenged
- 35:02that decision within 30 days in the 11th circuit.
- 35:07And ultimately, they were successful in that
- 35:11case because FDA admitted that they had not reviewed
- 35:15any other part of the application. And the court
- 35:20held, the panel held that that was arbitrary,
- 35:23that the FDA had in previous guidance indicated
- 35:26that they were going to review marketing plans
- 35:28and other data and weigh all the evidence that
- 35:34this study was required. And in the case of Biddy
- 35:36Vapor, what was unique about this case versus
- 35:39the other ones, most of which went towards for
- 35:42FDA, was that they had a very unique marketing
- 35:45strategy. They had a very robust youth access
- 35:48prevention plan. They had no evidence that kids
- 35:52or youth were using their products. They had
- 35:55significant evidence that adults, adult smokers
- 35:59who, which again, the target population of these
- 36:01products are adult smokers because we want them
- 36:03to use these products and quit smoking because
- 36:06these are much less harmful. But they were able
- 36:09to show the court, Biddy, that their products
- 36:13were much safer than cigarettes, were being used
- 36:18by adults, and that FDA had not considered their
- 36:21robust and unique marketing strategy. And the
- 36:24court held that that was arbitrary and vacated
- 36:29the MDO. In Fontum, U .S., in another case, in
- 36:33the D .C. Circuit, similar situation, company
- 36:38challenge, and MDO. This one was for tobacco
- 36:42flavors. And FDA said, when it comes to these
- 36:45tobacco flavors, the record evidence in the case
- 36:49demonstrated that FDA had not done a robust review
- 36:52of the application. They had not done a holistic
- 36:55review of the evidence and data presented in
- 36:58the application. And so while FDA denied their
- 37:01flavors as well, when it came to their tobacco
- 37:03flavors, FDA said, you need to do this more robust
- 37:06study, or sorry, more holistic review, which
- 37:09they hadn't done. That was another example of
- 37:12a case being, an MDO being vacated by the courts.
- 37:17The other case, I'll just quickly come for time,
- 37:19go straight to Wages and White Line. So this
- 37:21is the main case that, as you can see, went up
- 37:23to the Supreme Court last year. What happened
- 37:27in Wages was this was an open system company.
- 37:30So open systems are, here's an example of one
- 37:32of their products, a Vapetasia Killer Custard
- 37:35e -liquid, here on my slide. This is a bottled
- 37:39e -liquid. that is not sold with any kind of
- 37:42device or hardware. It is intended for use in
- 37:46an open system device. So if a consumer has their
- 37:49own open system e -cigarette, they can use this
- 37:53liquid. You can build the tank on their own and
- 37:56vape their own products. This is an example of
- 37:58an open system. What's interesting about open
- 38:00systems is that historically, they have not been
- 38:03a major concern for youth use. Where we saw kids
- 38:07and young people start to vape, It was primarily
- 38:11in pod systems and disposables, which were, again,
- 38:15much easier to use, much smaller devices. You
- 38:17could hide them, you know, if you're going to
- 38:19school, hide them from your parents. Open systems
- 38:22tend to be much bigger, clunkier, and again,
- 38:26much more, it was more of an enthusiast product.
- 38:29If you're a vaping enthusiast, like a cigar enthusiast,
- 38:33you would use an open system. But if you wanted
- 38:35a quick hit, you'd go to your gas station and
- 38:38buy a disposable. And so anyway, just want to
- 38:40bring that point up because this was an example
- 38:43of a case where there wasn't any evidence that
- 38:46kids were using the product. And so that company
- 38:49had their PMTA denied because, again, they did
- 38:53not have a comparative efficacy study in their
- 38:57application comparing their flavor to a tobacco
- 39:00flavor. And among the arguments raised was that,
- 39:04again, There was a lack of fair notice that this
- 39:06particular type of study was going to be a requirement.
- 39:11When FDA had previously said there was no required
- 39:14studies, FDA was going to instead review all
- 39:17the data and evidence and weigh that evidence
- 39:20before making a decision. They argued that FDA
- 39:24changed their position, that FDA, again, acknowledged
- 39:27that marketing plans were going to be a key factor
- 39:29in the PMT review, and it ended up not mattering
- 39:32at all. FDA failed to consider the reliance interest
- 39:35of the companies who had spent millions and millions
- 39:37of dollars working with FDA or basing their PMTs
- 39:42off of FDA guidance to basically end up in failure.
- 39:49Again, marketing plans were not considered, and
- 39:50then FDA came up with post -hoc justifications
- 39:56for denying products after the fact in the litigation
- 40:02itself. coming up with new reasons for companies,
- 40:07for new reasons that companies got their MDOs.
- 40:12And then there's an argument that FDA effectively
- 40:14enacted a de facto flavor ban by way of this
- 40:20requirement, because the practical effect of
- 40:24this requirement was that no flavors got authorized.
- 40:28And even today, only a couple have been authorized.
- 40:30They meant all flavor. And so was that a de facto
- 40:34ban, which really is a product standard that
- 40:38has to go through notice and comment rulemaking,
- 40:41right? Because FDA can't just ban products without
- 40:44going through the rulemaking process and going
- 40:48through comments, et cetera. So those arguments
- 40:51were made. When it came down to it, though, the
- 40:55only argument, the only issue before the Supreme
- 40:57Court, because there wasn't Again, I can't get
- 41:00into details here because of time. There was
- 41:02an en banc case in the Fifth Circuit. The Fifth
- 41:05Circuit held in favor of company wages on this
- 41:11particular issue, which was then appealed to
- 41:13the Supreme Court. And the Supreme Court held
- 41:179 -0 that when it comes to the issue of fair
- 41:20notice, that there was no surprise switcheroo,
- 41:24that there was no change in FDA's position based
- 41:29on the historical guidance. The court said, if
- 41:33you look at all the many, many public documents
- 41:36and guidance over the years and follow the chain
- 41:39of events, companies should have known that FDA
- 41:43was going to focus on flavors the way it did,
- 41:46and that therefore the denials, the MDOs, were
- 41:49reasonably consistent with the agency's prior
- 41:52guidance. and in terms of the type of scientific
- 41:55evidence required and this particular type of
- 41:57study. Okay, so the court said you should have
- 42:01known that sweet, you know, fruit flavored products
- 42:04were going to be subject to a higher authority
- 42:06specific studies and that was on the industry
- 42:10for not figuring that out. And so that case was
- 42:13in FDA's favor. A number of these issues though
- 42:16are still outstanding, including the flavor ban,
- 42:20rulemaking, argument, those issues were essentially
- 42:26remanded back to the Fifth Circuit. So there
- 42:28are now several cases pending before the Fifth
- 42:31Circuit challenge on those issues. And so the
- 42:35case is not over yet. We're still going to see
- 42:38what happens with those cases over the next several
- 42:41months. And this could very well end up back
- 42:45before the Supreme Court at some point in the
- 42:47near future. OK, so what products have actually
- 42:51been authorized? Well, this is actually breaking
- 42:53news because it just was announced maybe about
- 42:55a week ago. There are 41 authorized ENDS products
- 42:59now. And not really 41. It's really like seven
- 43:02products. And then each product has different
- 43:05components or flavored pieces to it. But a total
- 43:09of 41 different units have been approved by FDA
- 43:14or authorized by FDA, including Again, recently,
- 43:19a company called Glass, G -L -A -S, which is
- 43:24an independent company that is not associated
- 43:27with Big Tobacco and is not Juul, which is also
- 43:30not Big Tobacco, but is not necessarily considered
- 43:31a small company. Glass received their authorization
- 43:36just last week for a tobacco -flavored device
- 43:39that, as we'll see, has what's called built -in
- 43:42device access restrictions. So this is new push.
- 43:46from FDA to get companies to use built -in age
- 43:51-gating technology like Bluetooth or NFC chips
- 43:56that will prevent unauthorized use of a particular
- 43:59product. Very technical. Again, we don't have
- 44:05time to get into it today, but you're going to
- 44:07start to see more of those types of devices out
- 44:08there that use the same kind of technology you
- 44:10might see in your phone to lock a device so that
- 44:13Only the authorized user would be able to vape
- 44:16it. Notably, we do have some recent authorizations
- 44:22of menthol flavors, including Android Daily and
- 44:26Android AcePod, as well as the Juul menthol pod,
- 44:30which was recently authorized. So FDA has finally
- 44:32opened the door to menthol products, but not
- 44:35much more beyond that. OK, so what are the key
- 44:39features of products that are approvable or authorizable
- 44:42by FDA. Companies have to show that they are
- 44:45less toxic than cigarettes, that they are effective
- 44:50at delivering nicotine in order to get people
- 44:51to switch, but not so effective that they drive
- 44:56uptake of the product. So there's this balancing
- 44:59effect of what's called abuse liability. How
- 45:01likely is it that something is going to help
- 45:03smoke or switch but not be too effective? or
- 45:07too addictive that it could get non -users to
- 45:10become addicted. That's called abuse liability
- 45:14or addiction potential. Then you have global
- 45:19youth appeal. How are these products marketed?
- 45:21Again, that's why FDA so far, by and large, has
- 45:23only approved tobacco flavors because they're
- 45:25still really hesitant to approve flavors. And
- 45:28as we'll see in a moment, they just published
- 45:30a new guidance document on flavors. So companies
- 45:34that have Those strong marketing controls and
- 45:37manufacturing quality systems are also key features
- 45:40of successful PMTAs. Again, I mentioned this
- 45:45kind of new effort to build in age gating into
- 45:50the hardware itself. And so FDA has indicated
- 45:55in their memos that when it comes to non -tobacco
- 45:59flavors, that products with the device access
- 46:03restrictions would have a greater chance of getting
- 46:04authorized than if they didn't have that technology.
- 46:09So again, what we're seeing now is different
- 46:12types of technologies being promoted whereby
- 46:16they can either use a biometric tool, a fingerprint
- 46:19scanner, or a Bluetooth connection to your phone
- 46:23where you can do an ID check or a face check
- 46:26in order to unlock a device. to allow it to be
- 46:30used. And so again, it remains to be seen how
- 46:34effective this type of technology will be. There
- 46:36are concerns about privacy and whether or not
- 46:41this opens the door to more privacy issues and
- 46:44data collection, particularly from companies
- 46:48that are based in China and concerns about people
- 46:52suddenly giving away their information to tobacco
- 46:55companies. I mentioned that new guidance. So
- 46:58this was, again, this is also breaking news.
- 47:00This just came out about a week or so ago. FDA
- 47:03finally published an updated guidance on what
- 47:08they see as the requirements for flavored products.
- 47:11And here, in this new guidance, they're doubling
- 47:14down on, again, the comparative efficacy requirement.
- 47:18Again, the requirement that these products' flavors
- 47:20have to be compared to a tobacco flavor version.
- 47:25There are reasons why that may not make too much
- 47:27sense. I'm happy to discuss later. But basically
- 47:30what this guidance said, just to boil it down,
- 47:33FDA saying, OK, we might approve flavors in this
- 47:36industry, in this category. But there are certain
- 47:38flavors that, based on the data we're seeing,
- 47:41are potentially less attractive to youth. Menthol,
- 47:44mint, tobacco, obviously, which is the baseline.
- 47:48But maybe things like coffee, tea, or spice,
- 47:50those types of flavors. might have less youth
- 47:54appeal and so may not need to show as much additional
- 47:57benefit over and above the tobacco flavor. But
- 48:01the more risky flavors in FDA's mind, fruit,
- 48:04candy, dessert, other sweet flavors, are going
- 48:07to have to show an extraordinary amount of benefit
- 48:11to get authorized above a tobacco flavor. Because
- 48:14again, the presumption is that those products
- 48:17are being used by kids and are risky. This is
- 48:21probably true. I'm not going to say it's not
- 48:24true. However, the reality is the marketplace
- 48:28is 95 % candy, dessert, fruit flavors. Again,
- 48:36for adults, for adult -only locations. It's hard
- 48:42to find mint, or spice, or tea, or coffee -flavored
- 48:45e -liquids. Again, just based on survey data
- 48:47alone, unclear how FDA is concluding that these
- 48:53flavors are more attractive if they're just based
- 48:56on the fact that if you ask young people who
- 48:59vape what they vape, they're most likely going
- 49:01to say a dessert or fruit flavor because that's
- 49:04what's on the market. That's what is available
- 49:07to buy. The other ones are less hard to buy.
- 49:10The good news is youth vaping has continued to
- 49:14fall dramatically. So this is a bit of you know,
- 49:19conundrum for FDA because the narrative is that
- 49:25flavors are driving youth use. However, the reality
- 49:29on the ground is that ever since, you know, since
- 49:34the 2019 peak, when we had the epidemic, what's
- 49:37called the vaping epidemic with Juul being the
- 49:40main product being used by high schoolers, at
- 49:44that point in time, Almost 27 .5 % of high school
- 49:50students in 2019 had said in a survey that they
- 49:55had tried vaping an e -cigarette at least once
- 49:58in the last 30 days. That number has continued
- 50:02to fall dramatically. It was in late 2020 that
- 50:07the federal government changed the age to purchase
- 50:09tobacco from 18 to 21. That was a huge, huge
- 50:15change in the industry. Suddenly, companies that
- 50:21retailers around the country could not sell vaping
- 50:26products to 18 -year -olds, which was a source
- 50:30of these products getting into high schoolers.
- 50:33And so in late 2020, December 2020, that law
- 50:37was changed. It raised the age to 21. And since
- 50:41then, the youth vaping rate has continued to
- 50:44fall an hour down in 2025. This was just released
- 50:49about a month or two ago, down to 7 .1%. This
- 50:54is a slide that Altria published, which shows,
- 51:00again, just shows clearly how vaping and tobacco
- 51:04use has declined overall over the last 15 years.
- 51:11And again, you see the peak. of vaping in 2019
- 51:16and that since completely fallen off, there was
- 51:19a gap here in 2020 with COVID and has continued
- 51:23to decline rapidly along with smoking. The main
- 51:30thing that we're trying to stop here, cigarette
- 51:31smoking has fallen dramatically. No one could
- 51:34have imagined back in 2011 when almost 16 percent
- 51:38of high schoolers were smoking that you know,
- 51:42today we would have less than two percent of
- 51:46youth smoking cigarettes. That's a huge, huge
- 51:49public health victory, no matter how you cut
- 51:52it. So I mentioned, you know, there's some people
- 51:57questioning whether it makes sense for FDA to
- 52:01focus on this tobacco flavor comparison, and
- 52:05the argument being that the real comparator is
- 52:10combustible cigarettes. because vaping products
- 52:13are not inherently tobacco flavored. It kind
- 52:18of defies logic, but they don't actually contain
- 52:20tobacco. And so many people assume that tobacco
- 52:25flavors are the baseline. That's not the case.
- 52:27That's the case for traditional products like
- 52:29cigarettes and a menthol cigarette, which is
- 52:32based off of a traditional cigarette. But when
- 52:34it comes to vaping products, that actually doesn't
- 52:37is not how it works. These are just formulated
- 52:39e -liquids. And so again, the more appropriate
- 52:43public health comparison would be to a combustible
- 52:47cigarette, not to a tobacco -flavored e -cigarette,
- 52:50if that makes sense. Briefly, I'm going to talk
- 52:53about nicotine pouches, which are a growing category
- 52:57of products now in the marketplace. FDA has been
- 53:02a lot more comfortable approving these types
- 53:04of products than vaping products. The Zin is
- 53:09the number one pouch brand on the market. They
- 53:13received authorization from FDA in 2025. And
- 53:18similar to the vaping market, you have a lot
- 53:21of products on the market that are subject to
- 53:23the exact same. So when it comes to pouches,
- 53:26everything I've talked about today, the PMTA,
- 53:29the compliance policies, the requirements, all
- 53:32of those same requirements apply to pouches.
- 53:34There's no difference, except that when it comes
- 53:37to pouches, FDA is not requiring that tobacco
- 53:42flavored comparison. But this is a growing category.
- 53:48We've seen now more and more companies on the
- 53:52market submitting applications. And last September,
- 53:56September 2025, FDA announced a pilot program.
- 54:00to streamline the review of pouch PMTAs because
- 54:06they want to clear the backlog and they're getting
- 54:09a lot of pushback from the industry saying FDA
- 54:12was sitting on these applications for years and
- 54:14years and years and not approving them. Meanwhile,
- 54:17the black market was taking off. And so FDA announced
- 54:20last year that they were going to complete their
- 54:23reviews of certain pending applications from
- 54:26some of the larger companies to get more approved
- 54:29products on the market. And then the first decision
- 54:33to come out of that pouch pilot program was the
- 54:36On Plus, which is an Altria brand product that
- 54:39was authorized in several flavors again. And
- 54:43that company was able to show that they had significantly
- 54:46reduced toxicant levels compared to cigarettes.
- 54:50And that they also did their own longitudinal
- 54:52studies demonstrating significant success in
- 54:56getting both smokeless tobacco users. That's
- 55:00oral tobacco users to quit, as well as smokers
- 55:03to significantly reduce their cigarette consumption.
- 55:06So we'll see if FDA continues to approve more
- 55:09pouch products. Very quickly, I'll touch on enforcement.
- 55:14Again, when it comes to enforcement, this is
- 55:15an area where FDA does have authority to issue
- 55:19warning letters and import bans, civil money
- 55:22penalties. They can seize products that are unauthorized
- 55:25for sale. They can come after retailers and issue
- 55:27no tobacco sale orders. They can issue permanent
- 55:30injunctions for companies that continue to violate
- 55:32the law. We have seen increased enforcement over
- 55:37the last several years. Here's some headlines
- 55:40that have popped up in the newspapers you might
- 55:42have seen or online. So we are finally seeing
- 55:47significant enforcement of unauthorized products,
- 55:50products that don't have PMTAs and that are otherwise
- 55:54violating the law. And so I expect to see more
- 55:57enforcement over the coming years. I'm almost
- 56:01out of time, but I want to briefly touch on state
- 56:03regulation because this was intended to cover
- 56:05both federal and state law. The Tobacco Control
- 56:11Act contains a preemption provision that limits
- 56:16what the states are allowed to do. So when it
- 56:20comes to product standards, manufacturing, pre
- 56:23-market authorization, Those are all things that
- 56:26are squarely within the FDA's authority, the
- 56:28federal government's authority. When it comes
- 56:30to things that are related to the sales and use
- 56:33of the product, that is within the state's authority.
- 56:37And so you end up having a very complicated checkerboard
- 56:43of laws and regulations around the country, whereby
- 56:48different states have different requirements
- 56:51for licensing, for sales. you'll see flavor bans,
- 56:55you'll see other types of prohibitions that make
- 57:00it very difficult to navigate how to distribute
- 57:03these products or sell these products at the
- 57:05state level. At a high level, there are a number
- 57:10of states that have flavor bans. New Jersey,
- 57:13New York, California, which is not on here, is
- 57:16the main, well, here it is. California was one
- 57:19of the first states to pass a flavor ban a few
- 57:22years ago. They also have something called an
- 57:27unflavored tobacco product list. So if you go
- 57:29into a vape shop or a smoke shop in California,
- 57:32you should not be able to find non -tobacco flavors.
- 57:37If you do, it's because they're being sold illegally
- 57:41and it's part of this ongoing black market issue.
- 57:44But California was one of the first states to
- 57:46include a flavor ban, among others, probably
- 57:49about a dozen or so today. And then we also have
- 57:52several large local city bands, New York, Washington
- 57:57DC, Chicago. So again, it gets very complicated
- 58:00if you're trying to navigate how to sell these
- 58:02products and avoid places where it's otherwise
- 58:06illegal. Then you have a number of states that
- 58:10have passed and a growing number, because every
- 58:12year they're adding more, that are passing what
- 58:14are called certification, PMTA directories or
- 58:18certification laws. What does that mean? The
- 58:22states are recognizing that companies that may
- 58:26have pending applications may be subject to FDA
- 58:29enforcement discretion under that historical
- 58:32compliance policy I mentioned early on. And so
- 58:35we're seeing states pass laws that say, okay,
- 58:38if you can prove to us that your product was
- 58:42on the market prior to the deeming date in 2016,
- 58:45that it was subject to a pending application
- 58:47in 2020 or sometimes 2022 for synthetic nicotine.
- 58:51and that the application is still pending, it
- 58:53has not been denied by FDA, or if it has been
- 58:56denied, that you went to court and got the court
- 59:00to stay the denial. If you can show us you've
- 59:04met each of those criteria, then we will list
- 59:06the product on a directory that is the complete
- 59:11directory of what can be sold in the state. that
- 59:18makes those products quote unquote legal in this
- 59:20state. And so you have, here's a sampling of
- 59:24states that now have these types of laws in some
- 59:29way, shape or form. California I mentioned, they
- 59:32have what's called the UTL, the unflavored tobacco
- 59:35list. So on top of the flavor ban in California.
- 59:40Technically, the only tobacco -flavored products
- 59:43that can be sold in California need to qualify
- 59:46for the unflavored tobacco product list, which
- 59:49just went live at the beginning of this year,
- 59:512026. You can Google that and see what tobacco
- 59:57-flavored products are actually included on this
- 59:59list and are therefore legal to sell in California.
- 1:00:02Again, you have a number of other states, a dozen
- 1:00:04or so states here that have these laws and a
- 1:00:07bunch more that are proposed. So it looks like
- 1:00:11that's my last slide. It's two o 'clock. I know
- 1:00:15I'm out of time, but I'm more than happy to stick
- 1:00:18around and answer any questions. All right, that
- 1:00:25looks like that concludes today's presentation.
- 1:00:27Thank you so much, Azim, for an excellent presentation,
- 1:00:30and thank you so much to our audience. Have a
- 1:00:32great day, everybody. Thank you.